Legend Biotech Corp (LEGN)vsBeiGene, Ltd. (ONC)
LEGN
Legend Biotech Corp
$18.64
+0.59%
HEALTHCARE · Cap: $3.60B
ONC
BeiGene, Ltd.
$368.08
+0.66%
HEALTHCARE · Cap: $39.69B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 382% more annual revenue ($6.13B vs $1.27B). ONC leads profitability with a 10.7% profit margin vs -7.2%. ONC earns a higher WallStSmart Score of 64/100 (C+).
LEGN
Hold42
out of 100
Grade: D
ONC
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LEGN.
Margin of Safety
+80.0%
Fair Value
$1758.06
Current Price
$368.08
$1389.98 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 51.9% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Earnings expanding 166.7% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 29.6% year-over-year
Areas to Watch
0.0% earnings growth
Weak financial health signals
ROE of -25.9% — below average capital efficiency
Negative free cash flow — burning cash
Trading at 8.0x book value
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : LEGN
The strongest argument for LEGN centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 51.9% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on EPS Growth, Debt/Equity, PEG Ratio. Revenue growth of 29.6% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.
Bear Case : LEGN
The primary concerns for LEGN are EPS Growth, Piotroski F-Score, Return on Equity.
Bear Case : ONC
The primary concerns for ONC are Price/Book, P/E Ratio, Altman Z-Score. A P/E of 62.9x leaves little room for execution misses.
Key Dynamics to Monitor
LEGN profiles as a hypergrowth stock while ONC is a growth play — different risk/reward profiles.
ONC carries more volatility with a beta of 0.52 — expect wider price swings.
LEGN is growing revenue faster at 51.9% — sustainability is the question.
ONC generates stronger free cash flow (596M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (64/100 vs 42/100) and 29.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Legend Biotech Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology and other indications in North America and internationally.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?